

**S4 Table.** Univariable and multivariable analyses for overall survival

	Univariable		Multivariable	
	HR (95% CI)	p-value	HR (95% CI)	p-value
<b>Non-interventional variables</b>				
Age (yr)				
< 70	1		1	
≥ 70	2.04 (1.03-4.06)	0.041	1.92 (0.95-3.86)	0.069
Sex			Not included	
Male	1			
Female	0.82 (0.29-2.31)	0.702		
cN			Not included	
Negative	1			
Positive	0.66 (0.29-1.52)	0.331		
ypT				
ypT0-1	1		1	
ypT2+	3.82 (0.91-15.95)	0.066	3.33 (0.77-14.45)	0.109
ypN				
ypN1	1		1	
ypN2+	1.59 (0.73-3.49)	0.245	0.80 (0.23-2.73)	0.716
No. of positive lymph nodes				
< 3	1		1	
≥ 3	1.8 (0.90-3.59)	0.098	1.86 (0.64-5.44)	0.258
Pathological stage			Not included	
ypT0/is/a and ypN+	1			
ypIIIA (T1-4a, N1)	3.69 (0.45-30.09)	0.222		
ypIIIB (T1-4a, N2-3)	5.99 (0.81-44.51)	0.080		
ypIVA (T4b or M1a)	10.11 (1.2-85.09)	0.033		
<b>Interventional variables</b>				
Adjuvant				
Not done	1		1	
Done	1.28 (0.64-2.56)	0.479	1.32 (0.63-2.74)	0.463
Adjuvant regimen			Not included	
MVAC	1			
Others	2.2 (0.54-8.94)	0.272		
Surgery			Not included	
Radical cystectomy	1			
Partial cystectomy	0.3 (0.04-2.22)	0.240		
LND			Not included	
Standard	1			
Extended	0.67 (0.35-1.32)	0.249		
Limited	0.71 (0.16-3.09)	0.649		
No. of LNs harvested			Not included	
< 20	1			
≥ 20	0.83 (0.39-1.77)	0.632		
Surgical resection status				
R0	1		1	
R1	1.67 (0.73-3.81)	0.227	1.50 (0.63-3.57)	0.356

CI, confidence interval; HR, hazard ratio; LN, lymph node; LND, lymph node dissection; MVAC, methotrexate, vinblastine, doxorubicin, and cisplatin.